Reproductive Rights and the State
Getting the Birth Control, RU-486, and Morning-After Pills and the Gardasil Vaccine to the U.S. Market
Seiten
2013
Praeger Publishers Inc (Verlag)
978-0-313-39822-3 (ISBN)
Praeger Publishers Inc (Verlag)
978-0-313-39822-3 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Simultaneously examining four significant, never-before-combined case studies, this unique feminist analysis offers troubling revelations about the private-public interaction in U.S. policy affecting birth control drugs.
Reproductive Rights and the State: Getting the Birth Control, RU-486, and Morning-After Pills and the Gardasil Vaccine to the U.S. Market tackles a subject that remains controversial more than 60 years after "the pill" was approved for use in the United States. The first book to examine the politicization of the FDA approval process for reproductive drugs, this study maps the hard-fought battles over the four major drugs currently on the U.S. market.
To make her case, Melissa Haussman scrutinizes the history of the FDA and the statutes that have governed it, as well as interactions between the U.S. government, American pharmaceutical companies, and the medical community. The analysis centers on explaining how three reproductive drugs were kept off the U.S. market well after their efficacy had been proven, while the availability of the fourth, Gardasil, has less to do with helping girls than with preserving the financial wellbeing of Merck. Readers will come away understanding how, when it comes to reproductive drugs, women's health concerns have consistently taken a backseat to political agendas and corporate profits.
Reproductive Rights and the State: Getting the Birth Control, RU-486, and Morning-After Pills and the Gardasil Vaccine to the U.S. Market tackles a subject that remains controversial more than 60 years after "the pill" was approved for use in the United States. The first book to examine the politicization of the FDA approval process for reproductive drugs, this study maps the hard-fought battles over the four major drugs currently on the U.S. market.
To make her case, Melissa Haussman scrutinizes the history of the FDA and the statutes that have governed it, as well as interactions between the U.S. government, American pharmaceutical companies, and the medical community. The analysis centers on explaining how three reproductive drugs were kept off the U.S. market well after their efficacy had been proven, while the availability of the fourth, Gardasil, has less to do with helping girls than with preserving the financial wellbeing of Merck. Readers will come away understanding how, when it comes to reproductive drugs, women's health concerns have consistently taken a backseat to political agendas and corporate profits.
Melissa Haussman, PhD, is associate professor of political science at Carleton University, Ottawa, Canada.
Series Foreword
Acknowledgments
1 Introduction
2 History of the FDA and Drug Regulation in the United States
3 The Development of the Pill
4 U.S. Pro-Choice and Pro-Life Groups' Strategies since 1960
5 Problems with Mifepristone (RU-486) and Misoprostol (Cytotec), 1988–2000
6 The "Morning-After Pill," Plan B (Levonorgestrel) Formulation
7 Reverse Lobbying for Gardasil
8 Conclusion: Why a Feminist Historical Institutionalist Lens Is Important
Selected Bibliography
Index
| Erscheint lt. Verlag | 11.1.2013 |
|---|---|
| Sprache | englisch |
| Maße | 156 x 235 mm |
| Gewicht | 482 g |
| Themenwelt | Medizin / Pharmazie ► Pharmazie |
| Sozialwissenschaften ► Soziologie | |
| Technik | |
| ISBN-10 | 0-313-39822-4 / 0313398224 |
| ISBN-13 | 978-0-313-39822-3 / 9780313398223 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Pharmaceuticals, Diagnostics, Medical Devices
Buch | Hardcover (2023)
Wiley-VCH (Verlag)
CHF 109,95
lernfeldorientiert und fächerübergreifend 2. Schuljahr
Buch (2024)
Deutscher Apotheker Verlag
CHF 41,70
